These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7179 related articles for article (PubMed ID: 20432186)

  • 41. New therapeutic options in the medical management of advanced melanoma.
    Lutzky J
    Semin Cutan Med Surg; 2010 Dec; 29(4):249-57. PubMed ID: 21277538
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinicopathological relevance of BRAF mutations in human cancer.
    Pakneshan S; Salajegheh A; Smith RA; Lam AK
    Pathology; 2013 Jun; 45(4):346-56. PubMed ID: 23594689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Real-world treatment patterns and clinical outcomes in advanced cutaneous melanoma patients in France.
    Sassolas B; Leccia MT; Godard C; Benmahamed L; Flinois A; Levy-Bachelot L; Bédane C
    J Eur Acad Dermatol Venereol; 2018 Apr; 32(4):587-594. PubMed ID: 28960564
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A prolonged complete response in a patient with BRAF-mutated melanoma stage IV treated with the MEK1/2 inhibitor selumetinib (AZD6244).
    Boers-Sonderen MJ; Desar IM; Blokx W; Timmer-Bonte JN; van Herpen CM
    Anticancer Drugs; 2012 Aug; 23(7):761-4. PubMed ID: 22293660
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    Heppt MV; Siepmann T; Engel J; Schubert-Fritschle G; Eckel R; Mirlach L; Kirchner T; Jung A; Gesierich A; Ruzicka T; Flaig MJ; Berking C
    BMC Cancer; 2017 Aug; 17(1):536. PubMed ID: 28797232
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Melanoma treatment's changing landscape.
    Jenks S
    J Natl Cancer Inst; 2014 Jun; 106(6):dju176. PubMed ID: 24907389
    [No Abstract]   [Full Text] [Related]  

  • 47. A report from the 22nd Congress of the European Academy of Dermatology and Venereology (October 2-6, 2013 - Istanbul, Turkey).
    Rabasseda X
    Drugs Today (Barc); 2013 Oct; 49(10):667-77. PubMed ID: 24191258
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [New breakthroughs in Oncodermatology].
    Mortier L
    Ann Dermatol Venereol; 2010 Dec; 137 Suppl 4():S158-64. PubMed ID: 21193119
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Understanding current therapies in metastatic melanoma].
    Rodríguez R; Parra A; González S; Molgó M; Droppelmann N; Acevedo F; Peña J; Uribe P
    Rev Med Chil; 2016 Nov; 144(11):1448-1458. PubMed ID: 28394962
    [TBL] [Abstract][Full Text] [Related]  

  • 51.
    Ponti G; Manfredini M; Greco S; Pellacani G; Depenni R; Tomasi A; Maccaferri M; Cascinu S
    Anticancer Res; 2017 Dec; 37(12):7043-7048. PubMed ID: 29187493
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The role of BRAF mutation in patients with high-risk malignant melanoma treated with high-dose adjuvant interferon therapy.
    Akman T; Oztop I; Baskin Y; Akbarpour M; Unal OU; Oflazoglu U; Ellidokuz H; Lebe B
    Med Oncol; 2015 Jan; 32(1):440. PubMed ID: 25502087
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The new paradigm of systemic therapies for metastatic melanoma.
    Volpe VO; Klufas DM; Hegde U; Grant-Kels JM
    J Am Acad Dermatol; 2017 Aug; 77(2):356-368. PubMed ID: 28711086
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Melanoma and search for therapeutic targets].
    de la Fouchardière A
    Ann Pathol; 2011 Nov; 31(5 Suppl):S123-4. PubMed ID: 22054449
    [No Abstract]   [Full Text] [Related]  

  • 55. BRAF inhibitor activity in V600R metastatic melanoma.
    Klein O; Clements A; Menzies AM; O'Toole S; Kefford RF; Long GV
    Eur J Cancer; 2013 Mar; 49(5):1073-9. PubMed ID: 23237741
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Treatment of BRAF-mutated metastatic melanoma].
    Boyles TB; Svane IM; Bastholt L; Schmidt H
    Ugeskr Laeger; 2016 Aug; 178(35):. PubMed ID: 27592869
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Current advances and perspectives in the treatment of advanced melanoma.
    Livingstone E; Zimmer L; Vaubel J; Schadendorf D
    J Dtsch Dermatol Ges; 2012 May; 10(5):319-25. PubMed ID: 22432863
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Malignant melanoma: molecular cytogenetics and their implications in clinical medicine.
    Junkins-Hopkins JM
    J Am Acad Dermatol; 2010 Aug; 63(2):329-32. PubMed ID: 20633801
    [No Abstract]   [Full Text] [Related]  

  • 59. BRAF as therapeutic target in melanoma.
    Wellbrock C; Hurlstone A
    Biochem Pharmacol; 2010 Sep; 80(5):561-7. PubMed ID: 20350535
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Vemurafenib: a guide to its use in unresectable or metastatic melanoma.
    Keating GM; Lyseng-Williamson KA
    Am J Clin Dermatol; 2013 Feb; 14(1):65-9. PubMed ID: 23329082
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 359.